Global project leader, late vaccines and immune therapiesVaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZenecaGaithersburg, Maryland, United States
OC 76.1 - Chadox1 Exposure-Induced Neutrophil-Activating Peptide 2 (NAP2) Antibodies: Murine-Based Insights into The Pathogenesis of Thrombosis with Thrombocytopenia Syndrome (TTS)
Wednesday, June 28, 202310:15 – 10:30 ET
